{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-005594","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.096198+00:00","generated_at":"2026-06-18T09:21:13.023962+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected","bullets":["DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.","No serious adverse events reported; vaccine well tolerated to date.","Initial safety and antibody response update expected in Q2 2023.","First human test of C1-cell platform for vaccines; CEO notes increased interest from academia/industry."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-005594","json":"https://secwatch.observer/filing/0001437749-23-005594.json","markdown":"https://secwatch.observer/filing/0001437749-23-005594.md","text":"https://secwatch.observer/filing/0001437749-23-005594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/0001437749-23-005594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/dyai20230306_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:21:13.023962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}